PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival.

Abstract Radiotherapy alone is often used to treat early-stage glottic cancer (ESGC); however, the optimal radiation treatment schedule remains unknown. The National Comprehensive Cancer Network (NCCN) guidelines recommend both hypofractionated radiotherapy (HFX) and conventionally fractionated radiotherapy (CFX). We compared overall survival (OS) and treatment patterns among patients treated with HFX vs CFX for ESGC using a large national database.
PMID
Related Publications

Definitive hypofractionated radiotherapy for early glottic carcinoma: experience of 55Gy in 20 fractions.

Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment?

Outcomes of radiation therapy for T1 glottic carcinoma from an Italian regional series with doses ranging from 60 to 66 Gy.

Advantage of accelerated fractionation regimens in definitive radiotherapy for stage II glottic carcinoma.

Hypofractionated radiotherapy for T1N0M0 glottic cancer: retrospective analysis of two different cohorts of dose-fractionation schedules from a single institution.

Authors

Mayor MeshTerms

Dose Fractionation

Keywords
Journal Title journal of the national cancer institute
Publication Year Start




PMID- 28521361
OWN - NLM
STAT- MEDLINE
DA  - 20170518
DCOM- 20170705
LR  - 20170705
IS  - 1460-2105 (Electronic)
IS  - 0027-8874 (Linking)
VI  - 109
IP  - 10
DP  - 2017 Oct 01
TI  - Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer:
      Patterns of Care and Survival.
LID - 10.1093/jnci/djx042 [doi]
AB  - Background: Radiotherapy alone is often used to treat early-stage glottic cancer 
      (ESGC); however, the optimal radiation treatment schedule remains unknown. The
      National Comprehensive Cancer Network (NCCN) guidelines recommend both
      hypofractionated radiotherapy (HFX) and conventionally fractionated radiotherapy 
      (CFX). We compared overall survival (OS) and treatment patterns among patients
      treated with HFX vs CFX for ESGC using a large national database. Methods: We
      identified patients diagnosed with stage I-II (cT1-2N0M0) glottic cancer from
      2004 to 2013 within the National Cancer Data Base who were treated with either
      HFX (2.25 Gy/fraction to 63-65.25 Gy) or CFX (2.0 Gy/fraction to 66-70 Gy). The
      overall survival of patients receiving HFX vs CFX was compared using the log-rank
      test, multivariable Cox proportional hazards regression, and propensity score
      matching. All statistical tests were two-sided. Results: Among 10 212 included
      patients, 4030 patients (39.5%) received HFX and 6182 patients (60.5%) received
      CFX. Predictors for receipt of HFX included clinical T1 disease, recent year of
      diagnosis, and treatment at academic and higher-volume centers (all P < .001).
      Patients treated with HFX increased from 22.1% in 2004 to 58.0% in 2013. HFX was 
      associated with improved OS compared with CFX on univariate (five-year OS =
      77.1%, 95% CI = 75.2% to 78.8%, vs 73.5%, 95% CI = 72.1% to 74.8%, respectively, 
      log-rank P < .001) and multivariable analysis (HR = 0.89, 95% CI = 0.81 to 0.98, 
      P = .02), a finding confirmed on propensity score matching. Conclusions: HFX is
      associated with improved survival compared with CFX among patients treated with
      definitive radiotherapy for ESGC, particularly among patients with cT2 disease.
      HFX utilization increased over the study period; however, 40% of patients in our 
      cohort did not receive HFX in the most recent year of our analysis.
FAU - Bledsoe, Trevor J
AU  - Bledsoe TJ
AD  - Affiliations of authors: Department of Therapeutic Radiology (TJB, HSP, JMS, RHD,
      ZAH), Department of Surgery (WGY), and Department of Medicine (BAB), Yale
      University School of Medicine, New Haven, CT.
FAU - Park, Henry S
AU  - Park HS
AD  - Affiliations of authors: Department of Therapeutic Radiology (TJB, HSP, JMS, RHD,
      ZAH), Department of Surgery (WGY), and Department of Medicine (BAB), Yale
      University School of Medicine, New Haven, CT.
FAU - Stahl, John M
AU  - Stahl JM
AD  - Affiliations of authors: Department of Therapeutic Radiology (TJB, HSP, JMS, RHD,
      ZAH), Department of Surgery (WGY), and Department of Medicine (BAB), Yale
      University School of Medicine, New Haven, CT.
FAU - Yarbrough, Wendell G
AU  - Yarbrough WG
AD  - Affiliations of authors: Department of Therapeutic Radiology (TJB, HSP, JMS, RHD,
      ZAH), Department of Surgery (WGY), and Department of Medicine (BAB), Yale
      University School of Medicine, New Haven, CT.
FAU - Burtness, Barbara A
AU  - Burtness BA
AD  - Affiliations of authors: Department of Therapeutic Radiology (TJB, HSP, JMS, RHD,
      ZAH), Department of Surgery (WGY), and Department of Medicine (BAB), Yale
      University School of Medicine, New Haven, CT.
FAU - Decker, Roy H
AU  - Decker RH
AD  - Affiliations of authors: Department of Therapeutic Radiology (TJB, HSP, JMS, RHD,
      ZAH), Department of Surgery (WGY), and Department of Medicine (BAB), Yale
      University School of Medicine, New Haven, CT.
FAU - Husain, Zain A
AU  - Husain ZA
AD  - Affiliations of authors: Department of Therapeutic Radiology (TJB, HSP, JMS, RHD,
      ZAH), Department of Surgery (WGY), and Department of Medicine (BAB), Yale
      University School of Medicine, New Haven, CT.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Natl Cancer Inst
JT  - Journal of the National Cancer Institute
JID - 7503089
SB  - IM
MH  - Aged
MH  - *Dose Fractionation
MH  - Female
MH  - Glottis/*pathology/radiation effects
MH  - Humans
MH  - Laryngeal Neoplasms/*mortality/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Practice Patterns, Physicians'/*statistics & numerical data
MH  - Radiotherapy Dosage
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
EDAT- 2017/05/19 06:00
MHDA- 2017/07/06 06:00
CRDT- 2017/05/19 06:00
PHST- 2016/11/23 [received]
PHST- 2017/02/24 [accepted]
AID - 3611465 [pii]
AID - 10.1093/jnci/djx042 [doi]
PST - ppublish
SO  - J Natl Cancer Inst. 2017 Oct 1;109(10). doi: 10.1093/jnci/djx042.